ClinicalTrials.gg
CompletedNCT03459911Updated Nov 2, 2018

A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions

A Phase 1 interventional study of Cozaar 100mg Tablet and Losartan potassium 100mg in Healthy, sponsored by Pharmtechnology LLC. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-02.

Sponsored by Pharmtechnology LLC · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To demonstrate bioequivalence of single dose test formulation of Losartan potassium tablets (containing Losartan potassium 100 mg) of Pharmtechnology LLC, Republic of Belarus with reference Cozaar® (containing Losartan potassium 100 mg) of "Merck Sharpe \& Dohme B.V.", Haarlem, the Netherlands in normal, healthy, adult, human subjects under fasting conditions.To monitor adverse events and ensure the safety

Read the detailed description

Total 66 normal healthy adult subjects will be enrolled in the study. Subjects will be administered either the Test or the Reference Product with 200 mL of water in each period as per the randomization schedule. Subjects will fast for at least 10 hours prior to administration of the study drugs and for four (4) hours after administration of the study drugs during each study period. Standardized meals will be provided in each study period. Water will not be accessible to the subjects 1 hour to administration of the study drugs and 1 hour after administration of the study drugs in each period. A total of 29 blood samples will be withdrawn for pharmacokinetic profiling during each study period. The plasma concentrations of losartan and its carboxylic acid metabolite will be measured by a validated LC-MS/MS analytical method. ANOVA will be performed on log transformed pharmacokinetic parameters Cmax, AUC0-t, AUC0-∞, and 90% confidence interval will be constructed for the ratio of geometric least square mean of the Test and Reference products, obtained from the log-transformed data. Bioequivalence will be concluded if the ratio estimate as well as its 90% confidence interval, both falls within the acceptable range of 80.00% to 125.00% for Cmax, AUC0-t.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
03

In context

Lead sponsor

Pharmtechnology LLC is the lead sponsor of 27 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following criteria should be checked at the time of study entry. If any does not apply at the time of study entry, the subject must not be included in the study:

  1. Healthy adult human subjects, aged between 18 to 45 years (both inclusive).
  2. Subjects with (BMI) 18.5 to 24.9 kg/m2
  3. Subjects able and willing to comply with the protocol requirements.
  4. Subjects should not have any medical history of significant diseases.
  5. If subject is a female and is

    • of child bearing potential, she should be practicing an acceptable method of for the duration of the study as suggested by the investigator, such as a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier method), intrauterine device (IUD), or abstinence.

    OR

    • surgically sterile, bilateral tubal ligation done at least 6 months before the study should be documented.
  6. Subjects willing to voluntarily provide written .
  7. Subjects willing to undergo pre- and post-study physical examinations and laboratory investigations.
  8. Subjects who are non-smokers based on history.
  9. Subjects willing to adhere to the protocol and the following study requirements:

    • Should not consume xanthine containing products, such as coffee, tea, chocolate or soft drinks at least 48 hours prior to dosing (i.e. in-house monitoring and the remaining based on history) until the last sample collection.
    • Should not consume alcohol at least 48 hours prior to dosing (i.e. during in-house monitoring and the remaining based on history) until the last sample collection.
    • Should not consume grapefruit or its products at least 7 days prior to each dosing (i.e. during in-house monitoring and the remaining based on history) and until the last sample collection.
  10. Subjects having no medical history and no clinically significant abnormalities in general physical examination, laboratory assessments, 12-lead , chest X-Ray or vital signs.

Exclusion criteria

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If any of these apply at the time of study entry, the subject must not be included in the study:

  1. Subjects incapable of understanding the process.
  2. Female subjects with a positive pregnancy test at screening or positive serum β-HCG test (done at check-in of each study periods) or lactating females.
  3. Female subjects of who are unwilling or unable to use an appropriate method of as outlined in the inclusion criteria, at least 28 days prior to the first period dosing until the post-study follow-up (i.e. until 7 days from the drug administration in Period II). Use of hormonal contraceptives either oral or implants within 3 months prior to first period dosing will not be acceptable.
  4. Subjects with inadequate venous access in their left or right arm to allow the collection of all samples via venous cannula in the study.
  5. Subjects with abnormalities in resting heart rate (>100 beats/min or \<50 beats/min), blood pressure either hypotensive episode (systolic blood pressure \<90 mmHg or diastolic blood pressure \<60 mmHg) or hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥90 mmHg), oral temperature (\< 95.60F or > 990F) on the screening day.
  6. Subjects with history of psychiatric disorders, which are likely to limit the validity of consent to participate in the study, or limit the ability to comply with the protocol requirements.
  7. Subjects with any evidence of organ dysfunction or any deviation from normal in their physical or clinical evaluation including and X-ray results.
  8. Subjects who have taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within 30 days prior to the start of the clinical period and during the study period.
  9. Subjects with a known history of drug to losartan or any of the formulation.
  10. Subjects with a history of alcohol abuse and/or drug abuse or who are found urinary screen test positive for drugs of abuse (Amphetamines, Morphine, Benzodiazepines, Marijuana, Cocaine and Barbiturates) or are found with current alcohol abuse based on alcohol breath test.
  11. Subjects diagnosed to be 1 and 2 or (HBsAg) or (HCV) virus positive.
  12. Subjects with clinically significant abnormal haematological values [ (Hb), total white blood cells count (WBC), total red blood cells count (RBC), differential WBC count, count and hematocrit].
  13. Subjects with clinically significant abnormal laboratory values for serum creatinine, blood urea nitrogen (BUN), serum (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase (ALP), serum , serum glucose (fasting), and serum cholesterol.
  14. Subjects with clinically significant abnormal urine analysis, defined as the presence of RBC (>5/HPF), pus cells (>5/HPF), epithelial cells (>5/HPF), glucose (positive), ketones (positive), bilirubin (positive) and protein (positive) (unless the clinical investigator considers the deviation to be irrelevant for the purpose of the study).
  15. Subjects with a clinically significant past history or current medical condition of:

    1. Pulmonary disorders ( and asthma)
    2. Cardiovascular disorders (especially heart blocks, myocardial infarction, congestive heart failure and uncontrolled hypertension)
    3. Neurological disorders (especially epileptic seizures)
    4. GIT disorders (gastrointestinal bleeding, gastric/peptic ulcer)
    5. Renal and/or hepatic disorders
    6. Coagulation disorders
    7. Endocrine disorders (especially diabetes mellitus)
  16. Any history of difficulty in donating blood
  17. Any clinically significant illness during 3 months before screening.
  18. Subjects who participated in any other clinical investigation using experimental drugs or have bled more than 300 mL in the past 3 months
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Losartan potassium 100 mg Tablets

    Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.

    Drug: Losartan potassium 100mg

  • Active comparator
    Cozaar® (Losartan potassium)100 mg Tablets

    Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.

    Drug: Cozaar 100mg Tablet

Interventions

  • Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)

  • Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter for losartan

    Peak Plasma Concentration (Cmax)

    Time frame: 10 Days

  2. Pharmacokinetic parameter for losartan

    Area under the plasma concentration versus time curve from time 0 to the last measured concentration (AUC0-t)

    Time frame: 10 Days

Secondary outcomes

  1. Safety and tolerability of investigational products

    Number of adverse events, number of deaths, number of severe adverse events in subjects who have taken at least one dose of investigational products.

    Time frame: 17 Days

  2. Other pharmacokinetic parameters for losartan

    Area under the plasma concentration versus time curve from time 0 to to infinite time(AUC0-∞)

    Time frame: 10 Days

  3. Other pharmacokinetic parameters for losartan

    Time of maximum measured plasma concentration (Tmax)

    Time frame: 10 Days

  4. Other pharmacokinetic parameters for losartan

    Elimination or terminal half-life (T1/2)

    Time frame: 10 Days

  5. Other pharmacokinetic parameters for losartan

    Elimination rate constant (Kel)

    Time frame: 10 Days

  6. Other pharmacokinetic parameters for losartan

    Residual area (AUCresid)

    Time frame: 10 Days

07

Study locations

1 site
  • Clinical Unit, Reliance Life Sciences Pvt. Ltd.
    Mumbai, Maharashtra 400 701, India
08

References and documents

Individual participant data

Plan to share: Undecided — The Company may provide the individual participant data after privacy protection on case by case basis.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Mar 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2018
First posted
Mar 9, 2018
StartActual
Feb 16, 2018
Primary completionActual
Mar 11, 2018
CompletionActual
Mar 16, 2018
Last update
Nov 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03459911
Collaborators
Reliance Life Sciences Private Limited
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Feb 16, 2018
Primary completion
Mar 11, 2018
Completion
Mar 16, 2018
Last update
Nov 2, 2018

Study contacts

Suresh A Maroli, MD
principal investigator · Reliance Life Sciences Pvt. Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion